The Management of Gastro-oesophageal Reflux in Infants



Similar documents
GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Gastroesophageal Reflux Disease (GERD) and Barrett s Esophagus (BE)

Proton Pump Inhibitor Utilization Patterns in Infants

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Adoption by CHMP for release for consultation November End of consultation (deadline for comments) 31 March 2011

Public Assessment Report. Pharmacy to General Sales List Reclassification. Nexium Control 20mg Gastro-Resistant Tablets.

33 % of whiplash patients develop. headaches originating from the upper. cervical spine

Prepared by:jane Healey ( 4 th year undergraduate occupational therapy student, University of Western Sydney

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS

Figure 2: Recurrent chest pain of suspected esophageal origin

ESCMID Online Lecture Library. by author

How To Write A Systematic Review

Chapter 6 Gastrointestinal Impairment

Alison White Devang Rai Richard Chye

Intervention and clinical epidemiological studies

A PRACTICAL APPROACH TO CHRONIC COUGH IN CHILDREN

Figure 3: Dysphagia. 14 meets. esophageal. esophageal manometry +/- +/- impedance measurement. structural lesion? no. 19 yes

Clinical bottom line. For more detailed evidence on the effectiveness of injections for tennis elbow, please see the CAT on:

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Cochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment

Critical Appraisal of a Research Paper

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE TREATMENT OF DEPRESSION

PEER REVIEW HISTORY ARTICLE DETAILS

Tension Type Headaches

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial

NHS FORTH VALLEY Neonatal Oxygen Saturation Guideline

Management and Treatment Guidelines for Cornelia de Lange Syndrome

Motility Disorders that are Commonly Mistaken for Reflux by Susan Agrawal

G E R D. (Gastroesophageal Reflux Disease)

Female Urinary Incontinence

Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients

Glossary of Methodologic Terms

Riociguat Clinical Trial Program

FAILURE TO THRIVE DR. IBRAHIM AL AYED

CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

ASTHMA IN INFANTS AND YOUNG CHILDREN

Respiratory Concerns in Children with Down Syndrome

MIND-BODY THERAPIES FOR HYPERTENSION

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Failure to Thrive: Rethinking Our Treatment Goals Darren Fiore, MD 2013 Advances & Controversies in Clinical Pediatrics. Tips and Reference Sheet

Comparison/Control Groups. Mary Foulkes, PhD Johns Hopkins University

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

Treatments for Barrett s Oesophagus

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.

Participating in Alzheimer s Disease Clinical Trials and Studies

4/18/14. Background. Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients. Background. Signs and Symptoms of Withdrawal

The submission positioned dimethyl fumarate as a first-line treatment option.

Choosing a placebo EAPC Research Forum Trondheim 2008

1-800-HRT-BURN. understanding gerd. Is it just a little HEARTBURN. or something more serious? NEW

Bach Flower Remedies for pain relief and psychological problems

HYDROLYSATES IN EASY TO DIGEST FORMULAS

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Rapid Critical Appraisal of Controlled Trials

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Inhibit terminal acid secretion from parietal cells by blocking H + /K + - ATPase pump

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)

Prior Authorization Guideline

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

NEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Behavioral and Physical Treatments for Tension-type and Cervicogenic Headache

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author

100% WHEY PROTEIN PARTIALLY HYDROLYZED in Infant Formula and REDUCING THE RISK OF ALLERGY IN INFANTS EXECUTIVE SUMMARY

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.

Psychosocial treatment of late-life depression with comorbid anxiety

PATIENT REPORTED OUTCOMES IN ESOPHAGEAL DISEASE: AN OPEN SOURCE WEB BASED FRAMEWORK

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

Gastroesophageal Reflux in Infants and Children

What is critical appraisal?

Does training in workplace adjustment and posture prevent occupational overuse syndrome in workplace based computer users?

Behavioral Health Policy Phototherapy Light for the Treatment of Seasonal Affective (SAD) and Other Depressive Disorders

BEST in MH clinical question-answering service

Guidelines for oesophageal manometry and ph monitoring

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Gastroesophageal Reflux

SYNOPSIS. 2-Year (0.5 DB OL) Addendum to Clinical Study Report

Is manual physical therapy more effective than other physical therapy approaches in reducing pain and disability in adults post whiplash injury?

2. Background This drug had not previously been considered by the PBAC.

Remove this cover sheet before redistributing and replace it with your own. Please ensure that DPHHS is included on your HAN distribution list.

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

What are confidence intervals and p-values?

Transcription:

TSMJ Volume : Cases The Management of Gastro-oesophageal Reflux in Infants Yousef El-Gohary, Andrew Karwowski, Gracia Chong, Melissa Kern, Sara Molloy, Boitumelo Pule, th Year Medicine ABSTRACT Objective: To determine the optimal management of gastro-oesophageal reflux in infants. Methods: Searches were made on medical databases (Cochrane Library, National Electronic Library for Health, PubMed). Three randomised control studies, a case control study, an intervention study and one systematic review were chosen and appraised according to a critical appraisal checklist. Results: Antacids and feed thickeners were found to be effective in decreasing the symptoms, but not the gastric acidity associated with gastro-oesophageal reflux. There was no evidence supporting the use of positioning in decreasing symptoms. No evidence was found to support the use of pharmacological agents (metoclopramide, omeprazole) in the treatment of gastro-oesophageal reflux. Conclusion: The optimal management of gastro-oesophageal reflux in infants is parental reassurance and education. If essential, conservative measures such as feed thickeners and antacids may be employed. INTRODUCTION Gastro-oesophageal reflux (GOR) is a common self-limiting condition, affecting up to two thirds of infants, that usually resolves by six to 1 months of age (Figure 1). 1 It is usually a normal physiological process involving regurgitation and is described by the lay public as spitting up. This type of emesis is effortless where there is passive return of gastric contents into the oesophagus, and occurs by three major mechanisms: transient lower oesophageal sphincter relaxation, increased intra-abdominal pressure (for example, sneezing, coughing), or spontaneous free reflux. # of Infant Spilling Natural History of GOR in Infants 3 3 1 1 1 3 7 9 1 11 1 13 1 1 1 17 1 19 Months Figure 1. Natural History of Gastro-Oesophageal Reflux (adapted from Martin et al, ). Gastro-oesophageal reflux disease (GORD) on the other hand, which affects only 1 in 3 infants, is a pathological process manifested by poor weight gain, persistent respiratory symptoms and signs of oesophagitis (Table 1). Patients with mild, uncomplicated reflux can be diagnosed clinically and treated without further GORD Regurgitation with poor weight gain Apnoea & Cyanosis Wheezing Recurrent pneumonia Chronic cough Stridor Irritability Haematemesis Iron deficiency anaemia Failure to thrive Neck tilting (Sandifer s syndrome) GOR Regurgitation with normal weight gain No significant respiratory symptoms No signs or symptoms of oesophagitis No neurobehavioural symptoms Table 1. Differences between Gastro-Oesophageal Reflux (GOR) and Gastro-Oesophageal Reflux Disease (GORD) (adapted from Jung, 1). investigations. The typical clinical features include post-prandial, persistent but effortless non-bilious emesis, and regurgitation with normal weight gain. A good history and clinical examination will usually distinguish between GOR and other conditions with similar presentations, such as pyloric stenosis. The -hour ph study is considered the gold standard for confirming or excluding the presence of abnormal GOR. The reflux index, which is the percentage of total time that oesophageal ph is less than., provides the most efficient interpretation of the test, with a sensitivity of 9 percent, specificity of 1 percent. 3 Additional parameters that can be measured include number of reflux episodes, number of reflux episodes lasting more than five minutes, the mean duration of each reflux episode, and the duration of the longest reflux episode, within the -hour period.

The Management of Gastro-oesophageal Reflux in Infants Regurgitation with normal weig ht gain, examination in infants and no signs or symptoms of GORD in child Thickened feeds in infants Reassure parents on therapeutic co urse Upright positioning after feedings Dietary and lifestyle modification in children Persistent regurgitation with signs of failure to thrive or oesophagitis or respiratory symptoms Consider other diagnosis Evaluate based on suspicion Consider casein hydrolysate trial Upper GI examination to evaluate structure Figure 3. Barium Study of Infants in the Sitting and Prone Positions, Indicating the Reduced Likelihood of Gastro-Oesophageal Reflux Occurring in the Sitting Position. (adapted from Bishop, ). management of gastro-oesophageal reflux in infants, through a systematic review of recent studies. METHODS Improved Continue med ication for -3 months Trial of medication for -3 weeks Pediatric GI consult Reconsider diagnosis Endoscopy or ph probe N ot improved Figure. The American Family of Physicians Proposed Management in Infants Presenting with Gastro-Oesophageal Reflux and Gastro- Oesophageal Reflux Disease (adapted from Jung, 1). The American Family of Physicians (Figure ) recommends that parental reassurance and education about the widespread prevalence of physiologic (functional) GOR in infants, especially among those one to four month old, is the most effective management. Other conservative measures recommended include thickening of feeds, dietary changes, and positional changes (the prone position may decrease the incidence of reflux as demonstrated in Figure 3). If the infant does not improve and shows signs of failure to thrive, then various pharmacological interventions are recommended, and these include antacids, H receptor antagonists, proton pump inhibitors and prokinetic agents. The aim of our study was to determine the optimal Essential Questions All patients accounted for? Outcomes assessed blind? Design - Aims clearly stated? - Measurements valid & reliable? - Outcomes clinically relevant? Analysis Treatment groups comparable at baseline Were there deviations from planned treatment? Results analyzed by Intention to treat? Stat. significance assessed? Side effects? Medical databases, such as the Cochrane Library, the National Electronic Library for Health and PubMed were searched for relevant articles using the following keywords: GER, GOR, gastrooesophageal reflux, infant, treatment, drug names such as antacid, metoclopramide, H receptor antagonist and proton pump inhibitor. Of all articles found, the six most relevant to the clinical question were chosen. They included three randomised control studies (RCT), a case control study, an intervention study and one systematic review. They were then appraised according to a critical appraisal checklist. (Tables, 3 and ) a. Criteria for SR clearly stated? b. Literature review extensive enough? c. Was quality of studies assessed? d. Results of assessment included? e. Details of studies included in SR? f. Results of individual studies pooled correctly? Not reported g. Meta-analysis done? Not reported h. Do SR findings add up to more than a sum of individual studies? Table. Appraisal Methodology Checklist for the Systematic Review (SR). Article 1 Article Article 3 Table 3. Appraisal Methodology Checklist for the Three Randomized Control Trials (RCT).

TSMJ Volume : Cases Essential Questions - How were cases obtained? - Data collected in same way? Design Aims clearly stated? Measurements valid & reliable? Analysis Statistical significance assessed? Interpretation Biases? Confounding variables Article Article After diagnosis at research hospital - Questionnaire Socioeconomic class Table. Appraisal Methodology Checklist for the Article (the Case Control Study) and Article (the Intervention Study). Referred to research hospital Recall, measurement bias RESULTS The first article under review was a doubleblinded RCT assessing the efficacy and safety of aluminium-free alginate versus placebo in 9 infants with recurrent GOR. Infants were assessed at baeline and at seven and 1 days after initiation of treatment. Among patients randomised to receive alginate and patients to receive placebo, alginate was shown to be superior to placebo in reducing the number of reported vomiting or regurgitation episodes (p=.9) (Figure ). Although, treatment with placebo was also shown to reduce episodes, this effect did not achieve statistical signifcance. A trend in favour of alginate was also shown to reduce severity of vomiting (p=.1). The main criticism of this trial was that there was potential for observer bias, since the number of episodes of emesis were subjectively assessed by the parents on a diary card. It was nevertheless concluded that the treatment outcome after active alginate therapy in infants with GOR, was considered superior to placebo by both the investigators and parents. a. Criteria for SR clearly stated? b. Literature review extensive enough? c. Was quality of studies assessed? d. Results of assessment included? e. Details of studies included in SR? f. Results Comparison of individual of studies the Efficacy pooled correctly? of an Aluminum-Free Not reported g. Meta-analysis Paediatric done? Alginate Preparation and Placebo Not reported in Management of GOR h. Do SR findings add up to more than a sum of individual studies? Median Number of Vomiting/Regurgitation Episodes/ Hours 9 7 3 1 placebo alginate * baseline intervention Figure. Comparison of the Efficacy of an Aluminum-Free Paediatric Alginate Preparation and Placebo in the Management of Gastro- Oesophageal Reflux in Infants. The second article under review was a randomised, prospective double-blinded crossover trial investigating the efficacy of metoclopramide versus placebo in 3 infants 7. Several parameters were measured including the average daily occurrence of symptoms and the percentage of time that oesophageal ph was less than. (the Reflux Index), the total number of episodes in a -hour period, and the total number of reflux episodes lasting more than five minutes in each -hour period. The results show that metoclopramide produced a decrease in the reflux index (p<.1) (Figure ). However, a significant placebo response (p<.) was also shown with respect to daily symptom scores. 3 1 1 Investigation of of the the Efficacy of of Orally Administered Metoclopramide in in the the Treatment of of GOR in in Infants average daily occurrence of symptoms % time ph <. total # of episodes # of episodes lasting > minutes baseline placebo metoclopramide Figure. Investigation of the Efficacy of Orally Administered Metoclopramide in the Treatment of Gastro-Oesophageal Reflux in Infants The main criticisms with this study were that even though it stated that the sample size of 3 was justified, there was no description of how that number was arrived at. In addition, the randomization procedures were not described. Even though this was a crossover design, there was no washout period between switching of the

The Management of Gastro-oesophageal Reflux in Infants groups; hence there may have been some overlap between the effects of metoclopramide in the two groups. However the investigators concluded that there was no difference between the two treatment groups in any of the parameters except the reflux index. The third article was a double-blinded RCT assessing the efficacy of omeprazole in 3 irritable infants with GOR. Parameters that were assessed included the reflux index, a cry/fuss diary and a visual analogue scale of infant irritability, as judged by parental impression; these latter two measures were obtained at baseline and at the end of each two-week treatment period. Omeprazole treatment was shown to significantly lower reflux index in comparison with placebo (-.9 percent +/-. percent versus -1.9 percent +/-. percent, p<.1) (Figure ). No significant difference was shown in either the cry/fuss time or visual analogue measures. There was potential for observer bias in this study, since the cry/fuss diary and the visual analogue scale of infant irritability were subjectively judged by parental impression. However, it was concluded that compared with placebo, omeprazole significantly reduced oesophageal acid exposure but not infant irritability. Infant irritability improved with time, regardless of treatment. 1 1 1 1 Comparison of Omeprazole and Placebo in the Management of GOR in Infants Baseline Placebo Omeprazole Reflux Index Cry/Fuss Time (hr/ hr) Visual Analogue Scale Figure. Comparison of Omeprazole and Placebo in the Management of Gastro-Oesophageal Reflux in Infants. The fourth article was a case-control study comparing pre-thickened and home-thickened formulas in 1 infants with GOR. 9 Over a period of three months, infants were randomly selected to receive conventional formula with starch or prethickened infant formula. The investigators measured the effect of both pre-thickened and hone-thickened formula and the frequency of regurgitation mad vomiting. the progression of the patients symptoms were classified as cured, if initial symptoms disappeared or improved, when frequency of symptoms were reduced by percent or greater. Both types of thickened formula relieved reflux. Approximately half of the pre-thickened group and two-fifths of the homethickened group achieved cure. The small differenc in cure rates observed between groups was not significant (p=.97). Similarly only a small difference in rates of improvement was found between groups(p=1.) (Figure 7.). Also, the study was not blinded and the results were collected via a subjective questionnaire. 9 7 % 3 1 Comparison between Home-Thickened and Pre- Thickened Formulas in GOR Treatment HTF PTF HTF PTF Regurgitation Vomiting Figure 7. Comparison between Home-Thickened and Pre-Thickened Formulas in the Treatment of Gastro-Oesophageal Reflux in Infants. The fifth article was a prospective intervention study evaluating the effect of smaller volume, thickened formulas on GOR in 1 thriving infants. 1 Two parameters were measured, the number of emesis episodes in each -hour period and the reflux index. The study showed reduced vloume of formula decreased the frequency of emesis but not by a significant margin (p>.). However, additional modifications by thickening the small-volume feed, further decreased the frequency of emesis to a significant value compared to baseline (p<.) (Figure ). The sample size was justified and the results were consistent with previous reports, however this study was not randomised or blinded, thus introducing the potential for recall and measurement bias. In addition, the trial protocol required feeds that were strictly controlled, which was not applicable to the general population. 7 3 1 Small Volume, Thickened Formulas in the Management of GOR in Thriving Infants Reflux Index % time ph <. Figure. Small Volume, Thickened Formulas in the Management of Gastro-Oesophageal Reflux in Thriving Infants. improvement cure Baseline Unthickened Formula Thickened Formula 7

TSMJ Volume : Cases The sixth article was a systematic review of nonpharmacological Comparison and of Omeprazole non-surgical and Placebo therapies in thein 33 Management of GOR Infants infants with GOR. 11 It examined three main 1 aspects of conservative treatment: Baseline positioning, Placebo 1 thickened feeds * and formula changes. Omeprazole In terms of 1 positioning, three RCTs found that positional 1 changes have no proven efficacy in the treatment of GOR. With regard to thickened feeds, four randomized controlled trials indicated that there was a significant reduction in emesis with thickened feeds vs. unthickened feeds, however no significant difference was found in the amount of Reflux Index Cry/Fuss Time (hr/ Visual Analogue hr) Scale reflux. With formula changes, two RCTs showed that whey-based formulas significantly decreased emesis but had no effect on oesophageal ph (Table ). While inclusion criteria for this systematic review were provided, the outcome criteria were not. Other limitations of the study were a language and publication bias, since only English articles were considered. The outcomes were not comparable between the various studies as there was no description of a formal statistical method for assessing differences between the studies. Management Feed thickeners Positioning changes Formula change Antacids (alginate) Pro-Kinetic agents (metoclopromide) Proton Pump Inhibitors (omeprazole) H Receptor Antagonists Result emesis No effect emesis but no effect on oesophgeal ph number & severity of vomiting episodes No in daily symptoms or number of episodes but _ in time oesophageal ph <. oesophageal acid exposure but not irritability No studies found for use in infants Table. Summary of the Results in the Management of Infants with Gastro-Oesophageal Reflux. determined that the best line of treatment involves parental reassurance and education. No evidence was found to support the use of pharmacological agents in the treatment of GOR. Although both pro-kinetic agents and proton pump inhibitors may reduce oesophageal acid exposure, they do not have any effect on the symptoms of GOR, including infant irritability; which will improve with time, regardless of treatment. In contrast, this review found that antacids and feed thickeners were most effective in decreasing the symptoms, but not gastric acidity associated with GOR. There was no evidence supporting the use of positioning in decreasing the symptoms. When a parent presents to a doctor with an infant that vomits after every feed, he/she will find it difficult to accept that regurgitation is a normal occurrence. Providing parents with education surrounding this common and normal physiological process is essential to reducing their anxiety and concern. However, if an infant shows features of failure to thrive with persistent respiratory symptoms and signs of oesophagitis, which are manifestations of GORD affecting only 1 in 3 infants, then this would require admission and further evaluation. Gastro-oesophageal reflux is a self-limiting condition that usually resolves by six to 1 months of age. Infant irritability tends to improve with time, which could be a confounding factor in any study involving therapeutic intervention of GOR. Reassurance and parent education is paramount and should be the first-line of management. If parents insist, conservative treatment may be employed. DISCUSSION Following the review of current literature on the treatment of gastro-oesophageal reflux, it was REFERENCES 1. Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics ;19:11-7.. Jung A. Gastroesophageal reflux in infants and children. American Family Physician Dec 1, 1. (Accessed at: www.aafp.org/afp/111/13.html) 3. Al-Khawari HA, Sinan TS, Seymour H. Diagnosis of gastro-oesophageal reflux in children. Comparison between oesophageal ph and barium examinations. Pediatr Radiol ;3(11):7-7.. Bishop W. Gastroesophageal reflux (GER). Department of Pediatrics: the Vomiting Infant Lecture, University of Iowa,. (Accessed at: http://www.vh.org/pediatric/provider/pediatrics/pedsgi Disease/GER.html). Crombie IK. The pocket guide to critical appraisal: a handbook for health care professionals. London: BMJ Publishing Group, 199.. Miller S. Comparison of the efficacy and safety of a

The Management of Gastro-oesophageal Reflux in Infants new aluminium-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Curr Med Res Opin 1999;1:1-. 7. Tolia V, Calhoun J, and Kuhns L. Randomized, double-blind trial of metoclopramide and placebo for gastroesophageal reflux. J Pediatr 199;11:11-.. Moore D, Tao B, Lines D, Hirte C, Heddle M, Davidson G. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 3;13():19-3. 9. Penna F, Nortoh R, Carvalh A, et al. Comparison between pre-thickened and home-thickened formulas in gastroesophageal reflux treatment. J Pediatr 3;79(1):9-. 1. Khoshoo V, Ross G, Brown S, Edell D. Smaller volume, thickened formulas in the management of gastroesophageal reflux in thriving infants. J Pediatr Gastroenterol Nutr ;31:-. 11. Carroll AE, Garrison MM, Christakis DA. A systemic review of non-pharmacological and nonsurgical therapies for gastroesophageal reflux in infants. Arch Pediatr Adolesc Med ;1():19-13. 9